Cedazuridine

Research use only, not for human use.

Cedazuridine (E7727) is a novel cytidine deaminase inhibitor, and a componet of ASTX727 for treatment of hematologic malignancies.

Cedazuridine (E7727) is a novel cytidine deaminase inhibitor, and a componet of ASTX727 for treatment of hematologic malignancies.Blood Cancer Phase 2 Clinical.

Cedazuridine (Compound 7a) exhibits superior acid stability.Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, HY-10586) in growth inhibition of AML cell lines.

Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models. Animal Model:Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) modelsDosage:3 mg/kg Administration:Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days Result:Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model.Animal Model:NSGS male mice Dosage:1, 3, 10 and 30 mg/kg Administration:Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies) Result:Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.

E7727 | E 7727

Cell Cycle/DNA Damage

Nucleoside Antimetabolite/Analog

Nucleoside Antimetabolite/Analog

Cancer

Blood cancer

1141397-80-9

268.217

C9H14F2N2O5

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (186.42 mM)

O=C1N([C@H]2C(F)(F)[C@@H]([C@@H](CO)O2)O)CC[C@@H](O)N1

(4R)-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)-4-hydroxy-1,3-diazinan-2-one

(-20℃)

With Ice Pack

≥ 2 years